PPP treatment

PreclinicalBiologic

RRegenexx, LLC

PPP treatment is one of 47 biologic programs targeting Low back pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Low Back PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Low Back Pain

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

9 2

Aleve

Jazz Pharmaceuticals

Approved

5 3

Voltaren

Novartis

Approved

4 4

Advil

KKenvue Brands

Approved

13 5

Lioresal

Novartis

Approved

1 6

Toradol

Roche

Approved

1 7

Celebrex

PPhiladelphia Eye Associates

Approved

6 8

Oxycontin

PProtega

Approved

5 9

Bayer Aspirin

Zometa

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Low back pain1 trial

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

Terminated·RRegenexx, LLC·N/A·NCT03618979·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PPP treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PPP treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PPP treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regenexx, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: RRegenexx, LLC

PPP treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Low back pain1 trial

References

Drug Info

Quick Facts

Related News